Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO
Laurence Reid succeeds Steven Holtzman as Decibel sharpens focus of early R&D
Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders.
Reid told BioCentury that Decibel Therapeutics Inc.'s reorganization deprioritizes its early R&D in hearing protection and its tinnitus and synaptopathy-induced hearing loss programs. New targets and products entering the company's pipeline will be regenerative therapies for hearing loss and balance disorders, but the company will continue developing its clinical-stage therapy for hearing protection and its lead gene therapy